Plazomicin - Achaogen

Drug Profile

Plazomicin - Achaogen

Alternative Names: [14C]-plazomicin; ACHN-490; Plazomicin sulfate; ZEMDRI

Latest Information Update: 24 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Isis Pharmaceuticals
  • Developer Achaogen
  • Class Aminoglycosides; Antibacterials; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Urinary tract infections
  • Registered Pyelonephritis
  • Preregistration Bacteraemia; Nosocomial pneumonia
  • Preclinical Gram-negative infections
  • No development reported Respiratory tract infections; Tularaemia; Yersinia infections

Most Recent Events

  • 27 Jun 2018 Registered for Pyelonephritis (Treatment-resistant) in USA (IV)- First Global Approval
  • 27 Jun 2018 Registered for Urinary tract infections (Treatment-resistant) in USA (IV)- First Global Approval
  • 26 Jun 2018 Achaogen receives complete response letter from the FDA for Plazomicin in Bloodstream infection
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top